Get your free copy of the #influenza vaccine market survey report

Over 190 people responded to the 3rd annual Influenza Congress USA market survey, which was designed to give a complete overview of the commercial relationships in the influenza vaccine market.

Some interesting statistics:

• 35% of survey respondents thought that novel vaccine technology was a critical challenge for their business
• 30% thought that universal vaccines are critical to their future business
• 89.5% of respondents wanted to know more about innovative cell culture technology
• 80.5% listed clinical development or manufacturing as one of their top three challenges

If you want to know more about the influenza vaccine market, get your copy of the survey report now.

The survey respondents will be joining 150 other executives from pharma and biotech at the 3rd annual Influenza Congress USA 2011 in Washington D.C. this November.